McKesson Corporation
NYSE:MCKMedical - Distribution
-$28.96 today
- Market cap
- $125.21B
- Beta
- 0.32
- P/E (TTM)
- 19.3
- EPS (TTM)
- $39.00
- Dividend yield
- 0.44%
Volume 0.67M
Average 1.03M
MCK Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
McKesson CorporationNYSE: MCK
Depreciation & Amortization · Q1 FY2027 · quarter ended Jun 2026
Depreciation & amortization grows in line with its trailing trend
Q1 FY2027 depreciation & amortization of $195M rose 24.2% year over year, ahead of the +22.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 0.5% from the prior quarter. Over 3 fiscal years it compounded at +6.2% a year.
Context
- Depreciation & amortization amounted to 0.2% of revenue in FY2026, unchanged from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +24.2% holds above the trailing-twelve-month pace of +22.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2026
- 729M USD
- Year-over-year change
- +14.6%
- 4-year CAGR
- -1.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 729M | +14.6% |
| FY2025 | 2025-03-31 | 636M | +0.2% |
| FY2024 | 2024-03-31 | 635M | +4.4% |
| FY2023 | 2023-03-31 | 608M | -20.0% |
| FY2022 | 2022-03-31 | 760M | — |
Depreciation & Amortization vs competitors
How MCK compares with its peers on the latest reported figures
- MCK's LTM Jun 2026 depreciation & amortization of $767M is the 3rd largest of the 4 companies compared; the peer median is $970M.
- Its year-over-year change of +22.9% is the highest of 4, against a peer median of -1.5%.
- Depreciation & amortization amounts to 0.2% of revenue for MCK, versus a peer median of 0.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.07B | -1.5% | +14.6% | 0.3% | |
| LTM Sep 2026 | $970M | +15.3% | +11.4% | 0.4% | |
| LTM Jun 2026 | $767M | +22.9% | +6.2% | 0.2% | |
| LTM Mar 2026 | $169.63M | -32.6% | -2.1% | 6.2% | |
| Peer median (excluding MCK) | $970M | -1.5% | +11.4% | 0.4% | |
Competitors are the stored peer set for MCK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Net Income | 1.29B | 3.72B | 3.16B | 3.48B | 4.76B |
| Depreciation & Amortization | 760M | 608M | 635M | 636M | 729M |
| Deferred Income Tax | 34M | (20M) | (603M) | (110M) | 230M |
| Stock-Based Compensation | 161M | 162M | 0 | 0 | 0 |
| Change in Working Capital | 82M | 384M | (64M) | 1.16B | 162M |
| Accounts Receivables | (1.84B) | (1.08B) | (2.95B) | (3.94B) | (2B) |
| Inventory | (1.17B) | (1.26B) | (1.29B) | (2.27B) | (1.08B) |
| Accounts Payables | 2.8B | 3.79B | 0 | 0 | 4.32B |
| Other Working Capital | 292M | (1.06B) | 4.18B | 7.36B | (1.07B) |
| Other Non-Cash Items | 2.11B | 303M | 1.19B | 923M | 272M |
| Operating Cash Flow | 4.43B | 5.16B | 4.31B | 6.09B | 6.16B |
| Capital Expenditures | (535M) | (558M) | (687M) | (859M) | (745M) |
| Acquisitions (Net) | 572M | 210M | (225M) | 155M | (2.59B) |
| Purchases of Investments | (446M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 446M | 866M | 0 | 0 | 0 |
| Other Investing Activities | (126M) | (1.06B) | (416M) | (351M) | (101M) |
| Investing Cash Flow | (89M) | (542M) | (1.07B) | (733M) | (3.43B) |
| Debt Repayment | (1.15B) | (277M) | 56M | (21M) | 783M |
| Common Stock Issued | 220M | 163M | 116M | 101M | 89M |
| Common Stock Repurchased | (3.52B) | (3.64B) | (3.03B) | (3.15B) | (4.75B) |
| Dividends Paid | (277M) | (292M) | (314M) | (345M) | (381M) |
| Other Financing Activities | (1.38B) | (324M) | (175M) | (554M) | (372M) |
| Financing Cash Flow | (6.32B) | (4.37B) | (3.34B) | (3.97B) | (4.63B) |
| Effect of Forex Changes | (485M) | 495M | 6M | (16M) | (73M) |
| Net Change in Cash | (2.46B) | 744M | (94M) | 1.37B | (1.98B) |
| Free Cash Flow | 3.9B | 4.6B | 3.63B | 5.23B | 5.41B |
McKesson Corporation
NYSE:MCK
Intrinsic Alpha fair value
Locked
Current Price
$1,084.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.